These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs. North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587 [TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of boronic acid based inhibitors of autotaxin. Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182 [TBL] [Abstract][Full Text] [Related]
14. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138 [TBL] [Abstract][Full Text] [Related]
15. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977 [TBL] [Abstract][Full Text] [Related]
16. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816 [TBL] [Abstract][Full Text] [Related]
17. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Xu X; Yang G; Zhang H; Prestwich GD Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598 [TBL] [Abstract][Full Text] [Related]